A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved... The U.S. Food and Drug Administration has expanded ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...